

Fistulising Crohn's disease – initial, grandfather or recommencement (treatment break greater than 5 years) authority application



When to use this form

Use this form to apply for **initial**, **grandfather** or **recommencing** PBS-subsidised biological medicines for patients with complex refractory fistulising Crohn's disease who are either:

- initiating PBS-subsidised treatment
- **initiating** PBS-subsidised treatment for patient's who have received non-PBS-subsidised ustekinumab for the same condition prior to **1 January 2024**.
- recommending PBS-subsidised treatment after a treatment break greater than 5 years.

Important information

Authority applications to start or recommence PBS-subsidised treatment must be in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Applications for **balance of supply** can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Under no circumstances will phone approvals be granted for complex refractory fistulising Crohn's disease **initial**, **grandfather** or **recommencement** authority applications.

Where the term 'biological medicine' appears, it refers to adalimumab, infliximab or ustekinumab.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is ONLY for **initial** treatment, **grandfather** treatment or **recommencing** treatment after a treatment break greater than 5 years.

After a written authority application for the **first continuing** treatment has been approved, **subsequent continuing** treatments with PBS-subsidised biosimilar brands of biological medicines are **Authority Required (STREAMLINED)** and do not require authority approval from Services Australia for the listed quantity and repeats.

Section 100 arrangements for infliximab i.v. and ustekinumab i.v.

These items are available to a patient who is attending:

- an approved private hospital, or
- a public hospital

and is a:

- day admitted patient
- non-admitted patient, or
- patient on discharge.

These items are not available as a PBS benefit for in-patients of a public hospital.

The hospital name and provider number must be included in this authority form.

Treatment specifics

The assessment of the patient's response to the course of treatment must be conducted within the time frame specified in the restriction. Where a demonstration of response is not conducted within the required time frame, the patient will be deemed to have failed treatment with that particular PBS-subsidised biological medicine.

A patient who has experienced a serious adverse reaction of a severity necessitating permanent treatment withdrawal is not considered to have failed treatment with that PBS-subsidised biological medicine.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

PB092.2407 **1 of 5**



medicare



Fistulising Crohn's disease – initial, grandfather or recommencement (treatment break greater than 5 years) authority application

Pa	tient's details	Co	nditions and criteria	
1	Medicare card number Ref no.		qualify for PBS authority approval, the following ust be met.	conditions
	or	10	The patient is being treated by a:	
	Department of Veterans' Affairs card number		gastroenterologist	
			consultant physician specialising in gastro internal or general medicine)	enterology (either
2	Dr	11	This application is for:	
	Family name		adalimumab	
			infliximab i.v.	
	First given name		ustekinumab s.c with i.v. loading	Go to 13
			or	
•			ustekinumab s.c (grandfather only)	Go to 14
3	Date of birth (DD MM YYYY)		or	
			infliximab s.c. with i.v. loading	Go to 12
4	Patient's weight	12	The patient:	
	kg		has not received any prior PBS-subsidised	
			medicine treatment for this condition, and prescription for at least 2 i.v. doses of infli	
Pr	escriber's details		and 2 is attached	Ailliab at Weeks U
			or	
5	Prescriber number		is recommencing PBS-subsidised inflixim	nab after a
6	Dr Mr Mrs Miss Ms Other		treatment break, and an authority prescrip	tion for 1 i.v.
	Family name	40	dose of infliximab at weeks 0 is attached	
		13	The patient:	0.1.1
	First given name		has confirmed complex refractory fistulisir disease, defined by standard clinical, endo	•
	That given name		imaging features, including histological ev	idence, with the
_			diagnosis confirmed by a gastroenterologic physician specialising in gastroenterology	st or a consultant
7	Business phone number (including area code)		and	
			has an externally draining enterocutaneou	s or rectovaginal
	Alternative phone number (including area code)		fistula.	o o oo to ragilia.
				Go to 18
Но	spital details			
8	Hospital name			
	This hospital is a:			
	public hospital			
	private hospital			
9	Hospital provider number			

MCA0PB092 2407

Grai	ndfather treatment	Privacy notice	
15	Has the patient previously received non-PBS-subsidised treatment with ustekinumab for this condition prior to 1 January 2024? No	Personal information is protected by law (including the <i>Privacy Act 1988</i>) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, where it is required or authorised by law (including for the purpose of research or conducting investigations).	
[had confirmed complex refractory fistulising Crohn's disease, defined by standard clinical, endoscopic and/or imaging features, including histological evidence, with the diagnosis confirmed by a gastroenterologist or a consultant physician specialising in gastroenterology	More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy Prescriber's declaration	
	had an externally draining enterocutaneous or rectovaginal fistula	You do not need to sign the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos	
17 1 1	Has the patient demonstrated an adequate response to treatment with ustekinumab for this condition after receiving at least 12 weeks of initial non-PBS-subsidised therapy? No Yes Not applicable as patient has not had 12 weeks of non-PBS-subsidised therapy foo to 18 The patient has demonstrated an adequate response to treatment with ustekinumab evidenced by: a decrease from baseline in the number of open draining fistulae of greater than or equal to 50% and/or a marked reduction in drainage of all fistula(e) from baseline, together with less pain and induration as reported by the patient. cklist	 I declare that: I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine. I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application. I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction. the information I have provided in this form is complete and correct. I understand that: giving false or misleading information is a serious offence. I have read, understood and agree to the above. 	
18	The relevant attachments need to be provided with this form.	Date (DD MM YYYY) (you must date this declaration) Prescriber's signature (only required if returning by post)	
[Details of the proposed prescription(s). and The completed Fistula assessment form on page 4 of this form. 	Lin	
	or (grandfather applications only)	Debender this famous	
	The completed baseline Fistula assessment form on page 4 of this form prior to initiating non-PBS-subsidised treatment. and, if applicable The completed current Fistula assessment form on page 5 of this form no more than one month old at the time of application for patients who have received at least 12 weeks of non-PBS-subsidised treatment to demonstrate an adequate response to treatment.	Returning this form Return this form, details of the proposed prescription(s) and any relevant attachments: • online (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos or • by post (signature required) to Services Australia Complex Drugs Programs Reply Paid 9826 HOBART TAS 7001	





Fistula assessment form



Tiskulas sumankans museling kahla				
Number of externally draining complex fistulae				
Date of assessment (DD MM YYYY)				
Patient's full name				
PRINT IN BLOCK LETTERS				

Fistulae symptom grading table

Note: Each parameter in this table must be assigned a value

Symptom	Descriptions	Score	Subtotal
Discharge	no discharge	0	
	minimal mucous discharge	1	
	moderate mucous or purulent discharge	2	
	substantial discharge	3	
	gross faecal soiling	4	
Pain	no pain	0	
	mild discomfort	1	
	moderate discomfort	2	
	marked discomfort	3	
	severe pain	4	
Degree of induration	no induration	0	
	minimal induration	1	
	moderate induration	2	
	substantial induration	3	
	gross fluctuance/abscess	4	

Fistulae symptom grading total score



medicare

Fistula assessment form



PRINT IN BLOCK LETTERS				
Patient's full name				
Date of assessment (DD MM YYYY)				
Number of externally draining complex fistulae				
Fistulae symptom grading table				

Note: Each parameter in this table must be assigned a value

Descriptions	Score	Subtotal
no discharge	0	
minimal mucous discharge	1	
moderate mucous or purulent discharge	2	
substantial discharge	3	
gross faecal soiling	4	
no pain	0	
mild discomfort	1	
moderate discomfort	2	
marked discomfort	3	
severe pain	4	
no induration	0	
minimal induration	1	
moderate induration	2	
substantial induration	3	
gross fluctuance/abscess	4	
	no discharge minimal mucous discharge moderate mucous or purulent discharge substantial discharge gross faecal soiling no pain mild discomfort moderate discomfort marked discomfort severe pain no induration minimal induration substantial induration	no discharge 0 minimal mucous discharge 1 moderate mucous or purulent discharge 2 substantial discharge 3 gross faecal soiling 4 mo pain 0 mild discomfort 1 moderate discomfort 2 marked discomfort 3 severe pain 4 mo induration 0 minimal induration 1 moderate induration 2 substantial induration 3